India, June 3 -- Medicus Pharma Ltd (MDCX), a biotech/life sciences company, on Wednesday announced the submission of a Phase 2b SKNJCT-005 protocol under an existing investigational new drug (IND) application to the FDA for SkinJect in the treatment lesions associated with Gorlin syndrome.
Shares rose by over 15% on Wednesday, following the announcement.
Gorlin syndrome or Nevoid basal cell carcinoma (NBCC) is a rare genetic disorder associated with a lifetime development of multiple basal cell carcinomas and recurrent skin cancers. The disease effects approximately one in every 30,000 to 60,000 individuals worldwide.
SkinJect is a novel, localised immuno-oncology product developed for treating lesions caused by non-melanoma skin diseas...